Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
July 2026—Seegene launched its new antimicrobial resistance testing product, the Allplex MDRO assay. The assay, which is CE marked under the EU in vitro diagnostic regulation, is designed to identify key multidrug-resistant pathogens and associated resistance genes in a single run and can support same-day reporting, depending on laboratory workflow.
July 2026—Sysmex America has introduced the XR-Series, a hematology solution designed to help laboratories deliver fast, reliable results while maintaining efficient workflows. The next-generation XR-Series builds on the capabilities of the XN-Series, adding higher throughput, enhanced analytics, and complementary solutions that aim to streamline daily laboratory operations.
July 2026—Grifols launched at the International Society of Blood Transfusion Congress (Kuala Lumpur, Malaysia, June 20–24) the Evanzys IH, a modular, fully automated, track-enabled system designed to streamline operations and reduce manual intervention in immunohematology sample processing.
June 2026—Illumina launched DRAGEN version 4.5 software, designed to deliver new ways to reduce noise, improve accuracy, and extract biological signals.
The following customer bulletin about A1CNow+ Controls (REF 737) is published at the request of Nova-One Diagnostics.
June 2026—Qiagen has released the CE-IVDR-certified QIAstat-Dx BCID GPF Plus AMR panel.
June 2026—Anchor Molecular launched its BCR-ABL1 control panels designed to support laboratories in monitoring the performance of the quantitative detection of BCR-ABL1 translocation mRNA transcripts.
June 2026—Bruker announced at ESCMID Global 2026 (Munich, April 17–21) portfolio enhancements to its MALDI Biotyper workflow. The proprietary MBT Easy T kit, available for research use only or CE-IVD marked under the EU IVDR, is designed to simplify and standardize sample transfer steps to MALDI target plates. It includes ready-to-use reagents and applicators, supporting up to 2,000 samples, and features room-temperature storage.
June 2026—Artera has been granted the CE mark under the European Union in vitro diagnostic regulation for its ArteraAI Prostate Biopsy and ArteraAI Breast Cancer assays.
June 2026—Streck launched CD-Chex Daily, a ready-to-use quality control for flow cytometry laboratories. It provides coverage across 51 assayed, research-use-only markers in a single vial, with markers spanning surface, intracellular, and leukocyte scatter populations, including CD200, TRBC1, cMPO, CD27, CD36, CD81, cCD79a, CD79b, cKappa, cLambda, and others.
